Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Teva posts Q2 2026 GAAP loss on Emalex charge, raises innovative brand outlookJul 29Quarterly updatedeutetrabenazinefremanezumab-vfrm